Randall Moreadith sold $23k of SER
Chief Scientific Officer at AgeX Therapeutics, Inc.. 6,500 shares at an average of $3.61, traded Dec 2, 2025, filed Dec 4, 2025.
Score components
- +15RoleOfficer
- 0Trade size$23k at market
- +20Share of holdings soldSold 100% of holdings
- 0ClusterNo other insider selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -40.1%, 3m -54.8%, 6m -46.4%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001301120-25-000025, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Dec 2, 2025 | MOption exercise Common Stock10b5-1 | +1,500 | $0.06 | $90 | 1,500 | Dec 4, 2025 |
| Dec 2, 2025 | SOpen-market sale Common Stock10b5-1 | -1,500 | $3.91 | $5,858 | 0 | Dec 4, 2025 |
| Dec 3, 2025 | MOption exercise Common Stock10b5-1 | +5,000 | $0.06 | $300 | 5,000 | Dec 4, 2025 |
| Dec 3, 2025 | SOpen-market sale Common Stock10b5-1 | -5,000 | $3.52 | $18k | 0 | Dec 4, 2025 |
| Dec 2, 2025 | MOption exercise Stock Option (right to buy)derivative10b5-1 | -1,500 | $0.00 | $0 | 376,686 | Dec 4, 2025 |
| Dec 3, 2025 | MOption exercise Stock Option (right to buy)derivative10b5-1 | -5,000 | $0.00 | $0 | 371,686 | Dec 4, 2025 |
Related signals
Other insiders at AgeX Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 31Weak | SERbuy AgeX Therapeutics, Inc. | Stephen K. Brannan director | $2,030 1,000 shares | - | |
| 46Moderate | AgeX Therapeutics, Inc. | Jay Venkatesan director | $1,048 589 shares | - | |
| 36Weak | SERbuy AgeX Therapeutics, Inc. | Karen J Wilson director | $18k 10,100 shares | - | |
| 52Moderate | AgeX Therapeutics, Inc. | Karen J Wilson director | $37k 20,000 shares | - | |
| 46Moderate | AgeX Therapeutics, Inc. | Richard Peter Marshall director | $20k 12,183 shares | - | |
| 0Weak | AgeX Therapeutics, Inc. | Randall Moreadith Chief Scientific Officer | $19k 6,500 shares | -100% | |
| 10Weak | AgeX Therapeutics, Inc. | Randall Moreadith Chief Scientific Officer | $98k 39,000 shares | -100% | |
| 0Weak | AgeX Therapeutics, Inc. | Randall Moreadith Chief Scientific Officer | $20k 6,500 shares | -100% | |
| 0Weak | AgeX Therapeutics, Inc. | Randall Moreadith Chief Scientific Officer | $23k 6,500 shares | -100% | |
| 0Weak | AgeX Therapeutics, Inc. | Randall Moreadith Chief Scientific Officer | $7,375 2,500 shares | -100% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.